Literature DB >> 909668

Effect of terbutaline on cardiovascular state and uterine blood flow in pregnant ewes.

S N Caritis, E Mueller-Heubach, H O Morishima, D I Edelstone.   

Abstract

The cardiovascular and uterine hemodynamic effects of terbutaline, a beta-adrenergic receptor stimulant and labor inhibiting agent, were evaluated in the chronically instrumented, near-term pregnant ewe. The administration of terbutaline in the dose range required for labor inhibition in this species resulted in a mild maternal tachycardia and increase in pulse pressure without significant changes in uterine blood flow; uterine vascular resistance; or systolic, diastolic, or mean blood pressures. With infusion rates of terbutaline in excess of those required for labor inhibition, significant increases in maternal heart rate, pulse pressure, and systolic blood pressure were observed. Diastolic blood pressure decreased significantly during the higher infusion rates; however, uterine blood flow was unaffected. The minimal cardiovascular and uterine blood flow was unaffected. The minimal cardiovascular and uterine hemodynamic effects noted with the administration of terbutaline in the dose range necessary for labor inhibition indicate that this agent may possess advantages over several others currently in use for the treatment of premature labor.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 909668

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

Review 1.  Treatment of preterm labour. A review of the therapeutic options.

Authors:  S N Caritis
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

2.  Terbutaline pharmacokinetics in cows: preliminary data.

Authors:  Melanie J Boileau; Kevin E Washburn; Cyril R Clarke; Robert N Streeter; Lara K Maxwell
Journal:  Can J Vet Res       Date:  2007-01       Impact factor: 1.310

Review 3.  A risk-benefit assessment of therapies for premature labour.

Authors:  K Higby; C R Suiter
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.